US Pharma MarketingAfter Alzheimer's agitation nod, Axsome jacks up Auvelity's peak sales projection to $8B
Fresh off gaining an FDA expansion for Auvelity as a treatment for agitation associated with Alzheimer’s disease, Axsome Therapeutics has projected peak sales for the non-antipsychotic drug to reach $8 billion.
Fresh off gaining an FDA expansion for Auvelity as a treatment for agitation associated with Alzheimer’s disease, Axsome Therapeutics has projected peak sales for the non-antipsychotic drug to reach $8 billion.
Source: FiercePharma